Search Results

By 2011, she had established her own group within the Drug Discovery Biology theme at Monash Institute Why GPCR Spatial Signaling Is Changing Drug Discovery Today, Michelle leads the Spatial Organization understanding how signaling is organized in time and space, her team is opening doors to next-generation GPCR drug discovery and precision targeting. It’s a new language for drug discovery.

The field moved from single readouts to integrated signaling landscapes, accelerating drug discovery What started as hand-built assays on ice has become integrated platforms for drug discovery, systems

This week’s feature goes straight to the foundation: how system-level GPCR thinking  protects discovery Scientist—GPCR Pharmacology; Principal Scientist—In Vitro Pharmacology; Research Associate—Biologics Discovery Terry’s Corner: GPCR Pharmacology Insights That Prevent Real Drug Discovery Failures Discovery collapses

Through the Next Stage of its Evolution "New team focused on expanding its GPCR-focused structure-based drug concept in patients, and optimize value generation • Mid-term global expansion plans include drug discovery technology investments, licensing late-stage products for Japan, and strategic acquisitions

What started as a chemistry problem has evolved into a discovery platform.

December 2021 "30/11/2021 Confo will work together with Regeneron to apply its GPCR drug discovery platform to enable functional antibody discovery. protein-coupled receptors) in disease-relevant conformations, will be applied with the goal of enabling the discovery of novel therapeutic antibody drug candidates. " Read more at the source #DrGPCR #GPCR #IndustryNews

Read fast, apply faster, and stay ahead in GPCR drug discovery with evidence-based insights—no hype, Available in four formats, it turns a notoriously tricky measurement into something discovery teams can Discovery In neuroscience drug discovery, the right tool  can be just as critical as the right target discovery ➤ Why Dr. GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need

Drug discovery and development: Role of basic biological research. discovery. Allosteric modulation of GPCRs: From structural insights to in silico drug discovery. Biased signalling and allosteric machines: new vistas and challenges for drug discovery. Biased Allosteric Modulators: New Frontiers in GPCR Drug Discovery.

In recent years, pharmaceutical companies have begun to utilize cryo-EM for structure-based drug design pose particular challenges for X-ray crystallography, by cryo-EM has enabled insights into important drug

Discovery "Collaboration is part of Sosei Heptares’ Target Identification and Validation (TIV) strategy to leverage multiple sophisticated technologies that drive creation of new drug discovery programs in key therapeutic areas Kallyope, pioneers in drug discovery involving the gut-brain axis, will gain unique discovery involving the gut-brain axis, have entered a strategic research collaboration to identify and validate novel G protein-coupled receptor (GPCR) targets with a goal of creating new drug discovery

If you’re in GPCR discovery or biotech R&D, this is a masterclass in turning deep science into scalable Timeline: The Road to pHSense → Initial lanthanide probe design with Durham University (chemistry) → Discovery It’s a strategic tool for decoding GPCR behavior in drug discovery and systems biology.

Ingelheim take first steps towards collaborating to unlock orphan targets leveraging InterAx AI driven discovery agonists for a challenging orphan GPCR for a highly relevant therapeutic need. 💊 InterAx Biotech AG discovery

A central question of GPCR drug discovery is to understand what determines the agonism or antagonism small changes to the ligands that invert their pharmacological activity and thus helps to guide the drug discovery process. This approach can be readily applied to any drug target."

For drug discovery teams navigating safety margins, biased signaling, and combination therapy design, The Mechanistic Edge Behind Smarter Drug Discovery One of the most powerful aspects of this session is In drug discovery, orthosteric vs. allosteric isn’t just a mechanistic detail; it’s a decision that shapes Your membership gives you:   📚 Proven frameworks for real-world discovery 🌍 Flexible, on-demand lessons Here, you’ll get: Weekly lectures  that sharpen the tools you actually use in discovery A growing on-demand

into Collaboration Agreement with Domain Therapeutics and Université de Montréal for GPCR-Targeted Drug Discovery "Apr.19.2022 Ono Pharmaceutical Co., Ltd.

Therefore, the identification of such modulators as drug candidates is highly desirable. In this review, we aim to provide an overview of the recent progress in the discovery of biased modulators The challenges and methods for the discovery of TLR4 biased modulators are also outlined. fine-tune receptor conformation and signaling but also provide an opportunity to identify promising drug The discovery of biased modulators of TLR4 would provide insight for the future development of biased

discovery pipeline. Why Faster, Smarter Decisions Require More Than Kd In drug discovery today, the clock is always ticking Yet most discovery teams still rely on classic affinity metrics alone, often overlooking how kinetic discovery. You’ll gain clarity that accelerates your path from discovery to clinic: Know when your assays truly

Step into the world of drug discovery with Dr. In this foundational-level  lesson, Terry unpacks the real-life process behind discovering new drugs, You’ll explore: What makes a “discovery team” tick (and why teamwork is non-negotiable) The difference between Me Too  and First in Class  projects—and why both are essential Why target-based  discovery Don’t miss your chance to learn from one of the best: Unlock “Introduction to Drug Discovery" now

In GPCR drug discovery, a single mistaken assumption can derail an entire program. Why Misreading Antagonism Delays GPCR Drug Discovery If a dose-response curve shifts to the right, you Unlock “Competitive Antagonism” Now Only in Terry’s Corner Why Terry’s Corner For discovery-phase teams Monthly Ask‑Me‑Anything sessions with live Q&A An expanding on‑demand library for novices to expert drug hunters Influence over upcoming topics Who it’s for:  drug discovery teams, pharmacologists refining

residence time to diffusion-driven pharmacodynamics and the discovery of previously untargetable sites Change the Game For decades, drug design has treated GPCRs as surface targets. They’re the reason two equipotent drugs may perform very differently in vivo. Q&A An expanding on‑demand library of past lessons Influence over upcoming topics Whether you’re in discovery discovery.

The answer lies in a misunderstood property called efficacy—the power of a drug to trigger a response In Terry Kenakin’s latest lesson, you’ll uncover why efficacy is the unsung hero of drug discovery and

Welcome back GPCR fans, If your drug discovery strategy still relies on static GPCR models, you’re already Sharpen your discovery decisions ➤ GPCR Signal Transduction Call for Papers: Define What Comes Next Volume at Discovery On Target 2025, you’re missing where the field is headed. Register for Discovery On Target ➤ What our community is saying “I enjoy the breadth of questioning that GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who

discovery. Rational Drug Design One immediate application of this research lies in rational drug design . For example, orthosteric drug design —in which drugs bind to the receptor’s primary active site—can now Decoding GPCR Function: The Role of Mutagenesis in Rational Drug Discovery. Dr. GPCR Ecosystem; Dr. Ecosystem. https://www.ecosystem.drgpcr.com/post/decoding-gpcr-function-the-role-of-mutagenesis-in-rational-drug-discovery

Molecular innovation This Week’s GPCR Intelligence: The next edge in discovery isn’t louder exposure—it Kenakin from Terry's Corner shows how to tame irreversible drugs so their kinetic power works for you Your Membership Gives You: Proven frameworks used in real discovery programs On-demand lessons built It’s an operating system for discovery decisions, featuring practical frameworks, trusted curations, GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need

Think a drug just "locks into" a receptor and does its job? Think again. The Importance of Binding in Drug Action In pharmacology, binding must happen before any drug effect crucial for drug efficacy. Implications for Drug Development As drug developers, understanding these nuances can significantly impact The dynamic interplay of chemical forces shapes drug effectiveness.

Understanding the Connection Between Residence Time and Drug Efficacy: The Importance of Moving Beyond from its target When Potency Isn’t Enough Drug discovery teams are trained to chase nanomolar potency And drugs only work when they’re bound. In a world of fluctuating drug levels, residence time becomes the true predictor of effect. Unlock “Target Residence Time” Now Only in Terry’s Corner Why Terry’s Corner In a world where drug discovery

Antibody developers are increasingly utilising antibody libraries to derive high-quality, drug-like biologics However, only a few general-purpose libraries have been commercially available for drug discovery. The drugs also target relatively low-hanging fruit: like cytokines or tyrosine kinase receptors. To target hard-to-drug targets like G protein-coupled receptors (GPCRs), more libraries, including better

February 2022 Septerna emerges with $100M to spark 'second golden age' of prolific drug target GPCR with co-founder "Jan 27, 2022 07:00am Septerna wants to spark a second golden age in G-protein-coupled receptor drug discovery. Better known as GPCR, the fruitful research space has led to more than 700 approved drugs over previous Robert Lefkowitz, M.D., has 50 years of experience with the target and analogizes the search for new drugs

discovery, especially when experimental structures are unavailable. discovery involving novel drug-like molecules. While AlphaFold provides an excellent foundation for generating hypotheses in drug discovery, it is not Ligand discovery from a dopamine D3 receptor homology model and crystal structure. AlphaFold accelerated discovery of psychotropic agonists targeting the trace amine-associated receptor

December 2021 "Drug development is rarely trivial. Drugs that do make it to clinical trials have major hurdles to clear—not the least of which is safety It is necessary for drugs to evaluated for potential toxicities and side effects, and these key factors must be deemed tolerable before investigators can assess drug potency. Modern drug development approaches include a range of techniques leveraging structural biology, immunology